

1 **CAF to the rescue! Potential and challenges of combination antifungal therapy for**
2 **reducing morbidity and mortality in hospitalized patients with serious fungal**
3 **infections**

4
5

6 Samantha E. Jacobs¹ and Vishnu Chaturvedi^{2,3}

7

8 ¹ Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY,

9 USA

10 ² Microbiology and Molecular Biology Laboratories, Department of Pathology,

11 Westchester Medical Center, Valhalla, NY, USA.

12 ³ Department of Pathology, Microbiology, and Immunology, New York Medical College,

13 Valhalla, NY, USA.

14

15 Corresponding author:

16 Samantha Jacobs, MD, MS

17 Icahn School of Medicine at Mount Sinai

18 1 Gustave L. Levy Place, Box 1090

19 New York, NY, USA 10029

20 Phone: 212-241-0824

21 Samantha.jacobs1@mssm.edu

22 ORCID 0000-0002-9770-886X

23

24

25

26 **Abstract**

27

28 The global burden of invasive fungal disease (IFD) is substantial and escalating.
29 Combination antifungal therapy (CAF) may improve patient outcomes by reducing
30 development of resistance, improving drug penetration and rate of fungal clearance,
31 and allowing for lower, less toxic antifungal drug doses; yet, increased cost,
32 antagonism, drug-drug interactions, and toxicity are concerns. Clinical practice
33 guidelines recommend antifungal monotherapy, rather than CAF, for most IFDs due to a
34 lack of comparative randomized clinical trials. An examination of the existing body of
35 CAF research should frame new hypotheses and determine priorities for future CAF
36 clinical trials. We performed a systematic review of CAF clinical studies for invasive
37 candidiasis, cryptococcosis, invasive aspergillosis, and mucormycosis. Additionally, we
38 summarize findings from animal models of CAF and assess laboratory methods
39 available to evaluate CAF efficacy. Future CAF trials should be prioritized according to
40 animal models showing improved survival and observational clinical data supporting
41 efficacy and safety.

42

43 **Introduction**

44

45 **Continued dismal outcomes for patients with serious fungal infections**

46 The global burden of invasive fungal disease (IFD) is substantial, causing
47 approximately 1.5 million deaths per year, and escalating due to a growing population of
48 immunosuppressed individuals, global health events such as the COVID-19 pandemic,
49 and improvements in molecular diagnostics leading to increased reporting of previously
50 unrecognized or undiagnosed IFD.(1-6)

51 IFDs have considerable economic impact in terms of direct medical costs,
52 productivity loss, and pre-mature deaths.(7) In 2019, the estimated economic burden of
53 fungal disease in the U.S. was \$11.5 billion, and the mean cost of an inpatient visit
54 associated with fungal disease diagnosis was more than twice that of the average
55 inpatient stay. Within the healthcare system, IFDs lead to increased length of stay and
56 mortality, and inappropriate empirical antimicrobial therapy.(8-10) Disparate mortality
57 rates are observed across continents and countries. For example, 30-day all-cause
58 mortality in patients with candidemia is approximately 30% in Europe and the U.S. and
59 60-72% in South Africa and Brazil.(11)

60 **Potential and challenges of combination antifungal therapy**

61 Given the considerable individual and public health burden of IFDs, emphasis on
62 research pertaining to antifungal therapeutics is essential. Except for cryptococcal
63 meningitis, current clinical practice guidelines recommend antifungal monotherapy for
64 most IFDs; yet, morbidity and mortality remains unacceptably high.(12-19) Combination
65 antifungal therapy (CAF) is one putative strategy to reduce risk and improve outcomes.
66 Potential reasons to pursue CAF for IFDs are: (1) To broaden the spectrum of activity

67 for empirical therapy, (2) to enhance the rate of killing through antifungal synergy/
68 increased potency, (3) to delay or prevent development of resistance (4) to reduce
69 antifungal toxicity by using lower drug dosages (5) or to enhance the effectiveness of
70 older antifungals, and (6) to treat breakthrough infections.(20-23)

71 CAF may be particularly useful in difficult clinical situations, e.g., infections due to
72 highly resistant pathogens or biofilm formation, or in tissues with compromised drug
73 penetration. However, some potentially harmful effects of CAF include reduced fungal
74 killing (antagonism), drug-drug interactions, increased toxicity, and increased cost.

75 The concept of combining drugs with different mechanisms of action to treat a
76 disease is a longstanding practice supported by rigorous randomized controlled trials
77 (RCTs) for other complex and severe infections including HIV and tuberculosis, as well
78 as oncologic diseases.(24-27) Unfortunately, multiple challenges to conducting large-
79 scale RCTs exist for patients with IFDs including cost, the significant time to conduct the
80 study, particularly for rare fungi (e.g., Mucorales), and difficulty enrolling medically
81 complex and/or critically ill patients.(28) Due to a lack of RCTs comparing CAF to
82 monotherapy, CAF is reserved for salvage therapy or specific severe disease
83 manifestations, e.g., *Candida* endocarditis, in U.S. and international guidelines.(13)

84 To frame new hypotheses and carefully inform clinical trial design, it is important
85 to examine and build upon the existing body of preclinical research and human studies.
86 We perform a systematic review of CAF clinical studies for the most prevalent and
87 dangerous fungal pathogens, *Candida* spp., *Cryptococcus neoformans*, *Aspergillus*
88 spp., and the Mucorales. We further summarize findings from experimental research

89 and assess laboratory methods available to evaluate CAF efficacy. Table 1 provides a
90 “bird’s eye view” qualitative summary of the evidence for CAF.

91 **Clinical studies of combination antifungal therapy**

92 *Systematic review methods*

93 A systematic review to identify clinical studies of CAF for invasive candidiasis
94 (IC), cryptococcosis, invasive aspergillosis (IA), and invasive mucormycosis was
95 conducted in accordance with the PRISMA guidelines.(29) PubMed was searched for
96 English-language publications using the following terms “antifungal combination
97 therapy” or “combination antifungal therapy” and “candida” or “candidiasis”,
98 “cryptococcus” or “cryptococcosis” or “cryptococcal”, “aspergillus” or “aspergillosis”, and
99 “mucorales” or “mucormycosis” or “zygomycetes” or “zygomycosis” (Appendix). We
100 limited our search to manuscripts published between January 1, 2003 (coinciding with
101 the year of U.S. FDA approval of voriconazole) and February 1, 2023. Reference lists
102 from the included studies were additionally screened to identify potentially relevant
103 evidence. We included studies whose primary aim was to evaluate the CAF efficacy for
104 proven or probable IFD according to consensus definitions; fungal speciation was not
105 required.(30, 31) Papers were excluded if they were literature reviews or meta-
106 analyses, if they did not specify antifungal drug dosages, or if they evaluated
107 combinations including non-systemic antifungal agents, e.g., topical or aerosolized
108 formulations, or non-antifungal chemical compounds.

109 *Systematic review results*

110 The PRISMA flowcharts in the Appendix provide a detailed breakdown of the
111 results of the primary search for each of the four IFDs. From 954 publications evaluated,
112 104 articles met the inclusion criteria. These included 21 CAF papers for IC, 17 for
113 cryptococcosis, 45 for IA, and 21 for mucormycosis. Below, we focus our discussion on
114 the findings from randomized trials and large observational studies for each pathogen.
115 Details of each included manuscript, including study design, patient population,
116 antifungal therapy, and patient-related outcomes, are provided in Supplementary Tables
117 1-4.

118 *Invasive Candidiasis*

119 Only one RCT of CAF for IC was identified in the systematic review, and the trial
120 was conducted prior to the availability of echinocandins. The trial included 219 non-
121 neutropenic patients who received fluconazole (FLC) 800 mg/d plus placebo vs. FLC
122 plus deoxycholate amphotericin B (dAmB) 0.7 mg/kg/d for candidemia (*C. albicans* in
123 62%).(32) There was no difference between groups in the primary analysis of time-to-
124 failure, nor in mortality, although overall success rates were higher in the combination
125 vs. monotherapy arm (69% vs. 56%, respectively, $P=0.043$).

126 Further clinical data pertaining to CAF for IC was limited to 20 case reports and
127 small case series, most often describing azole-echinocandin or polyene-echinocandin
128 combinations used as salvage therapy. Four case reports and a series of 13 patients
129 with peritoneal dialysis-associated *Candida* peritonitis described favorable outcomes in
130 patients treated with combination dAmB or liposomal AmB (L-AmB) plus flucytosine (5-
131 FC), a regimen still recommended for treatment of deep-seated *Candida* infections, e.g.,
132 meningitis and endocarditis, based on limited experimental and clinical data.(13, 33-37)

133 This combination has shown synergy *in vitro* and is widely used for cryptococcal
134 meningitis (CM).(38) Moreover, excellent 5-FC levels are achieved in cerebrospinal
135 fluid (CSF).(39)

136 *Cryptococcosis*

137 The systematic review identified 12 RCTs and one prospective, non-randomized
138 trial of induction therapy for CM, all in individuals with HIV/AIDS, as well as 3
139 retrospective studies and a case report in persons with other immunocompromising
140 conditions. There are no prospective trials in persons without HIV, nor has CAF been
141 evaluated for other manifestations of cryptococcosis, e.g., pulmonary disease.

142 Several trials established that the combinations of AmB plus 5-FC and AmB plus
143 FLC both achieve improved clinical outcomes as compared to AmB alone.(40-42)
144 However, fungicidal activity, as measured by the rate of reduction in CSF yeast CFU
145 from serial quantitative cultures, is greater with AmB plus 5-FC as compared to AmB
146 plus FLC.(40, 41)

147 Combination 5-FC and FLC is appealing due to its oral availability and low rates
148 of nephrotoxicity, although prolonged 5-FC is associated with leukopenia.(43) In a
149 pivotal trial in Africa (ACTA) including 721 patients, the all-oral induction regimen of FLC
150 1200 mg/d plus 5-FC 100 mg/kg/d was non-inferior to dAmB plus FLC or 5-FC for 7 or
151 14 days for the primary endpoint of 2-week mortality.(44) However, faster CSF
152 clearance was observed with AmB plus 5-FC compared to FLC plus 5-FC.

153 L-AmB was investigated in a landmark trial, Ambition, in 844 individuals with CM
154 in sub-Saharan Africa. A single 10 mg/kg dose of L-AmB plus 14 days of high-dose FLC

155 and 5-FC was non-inferior to the WHO-recommended 1-week regimen of dAmB plus 5-
156 FC and was associated with fewer adverse events.(45) Following the results of the
157 ACTA and Ambition trials, as well as advocacy efforts, generic 5-FC is more widely
158 available at a reduced cost and utilized in routine care.(46)

159 Three-drug combinations of AmB, 5-FC, and FLC have also been studied. While
160 the triple therapy had the most potent fungicidal effect in a murine model of CM, it was
161 not more efficacious than AmB plus 5-FC in humans.(40, 47)

162 Other triazole antifungal agents have excellent *in vitro* activity against
163 *Cryptococcus* spp., and the combination of AmB and voriconazole (VOR) had similar
164 early fungicidal activity as compared to AmB plus 5-FC and AmB plus FLC in a small
165 randomized trial.(48, 49) However, VOR, isavuconazole (ISA), and posaconazole
166 (POS) have more side effects and drug-drug interactions, and higher costs than FLC,
167 thus limiting their utility for a disease that is most prevalent in resource-limited settings.

168 *Invasive Aspergillosis*

169 Two randomized trials, 10 observational studies, and 33 case reports/series met
170 inclusion criteria in the systematic review of CAF for IA.

171 Prior to widespread use of VOR as standard of care, prospective studies
172 primarily investigated polyene-echinocandin combination. In the randomized, open-
173 label Combistrat trial including 30 patients with hematologic malignancy (HM) and IA,
174 those receiving L-AmB 3 mg/kg/d plus caspofungin (CAS) had higher favorable
175 response rate (67%) and less acute kidney injury than those receiving high-dose L-AmB
176 10 mg/kg/d alone (27%, P=0.028 for comparison) for primary therapy.(50) However, L-

177 AmB \geq 7.5 mg/kg/d plus CAS combination led to poorer clinical outcomes compared to
178 POS suspension for salvage therapy in a single center compassionate use trial.(51)
179 Further clinical trials with polyene-based combination therapy have not been pursued in
180 the past two decades given a lack of compelling preclinical data, high rates of AmB-
181 associated nephrotoxicity, and studies confirming improved IA-related mortality with
182 VOR.(52, 53)

183 Observational studies of echinocandin-triazole combination therapy for IA have
184 had inconsistent results depending on the indication and study population. Marr and
185 colleagues compared VOR plus CAS to VOR alone in 47 patients with HM and
186 hematopoietic cell transplant (HCT) recipients with IA who had failed initial therapy with
187 AmB. Improved 3-month survival was observed in the combination group compared to
188 monotherapy (HR, 0.42; 95% CI, 0.17–1.1; $P=0.048$), independent of other variables
189 associated with prognosis.(54) However, in a retrospective study spanning 12 years
190 (1998-2010), VOR plus CAS did not achieve better outcomes than VOR alone, as
191 primary or salvage therapy.(55) In solid organ transplant recipients, compared to a
192 historical cohort receiving L-AmB alone, VOR plus CAS for primary therapy of IA led to
193 similar overall survival at Day 90 (67.5% combination vs. 51% L-AmB monotherapy
194 controls; $P=0.117$). (56)

195 To date, one RCT has evaluated echinocandin-triazole combination for IA. This
196 multicenter, multinational study randomized patients with HM or HCT recipients to VOR
197 plus anidulafungin (AFG) versus VOR alone for primary therapy of proven or probable
198 IA.(57) Amongst 277 patients, there was no difference in 6-week mortality
199 (combination: 19.4%, monotherapy: 27.5%; $P=0.087$). However, in a post-hoc

200 subgroup analysis of probable IA cases (n=218), 6-week mortality was lower in the
201 combination arm (15.7% vs. 27.3% monotherapy; $P=0.037$). A limitation of this trial is
202 that statistical power was lower than expected due to higher than expected mortality in
203 both treatment arms.

204 Polyene-triazole combination therapy has received relatively little study in
205 humans given the preclinical data demonstrating variable synergistic interactions.(58)
206 The only comparative data are from a retrospective study in which similar 12-week
207 survival was observed among 49 patients receiving L-AmB 3 mg/kg/d plus VOR or POS
208 vs. L-AmB plus CAS vs. VOR plus echinocandin.(59)

209 Taken together, these single studies have failed to decisively establish a benefit
210 to CAF for IA; however, limitations in study design may preclude definitive
211 determination.

212 *Mucormycosis*

213 Twenty-one manuscripts, including 6 retrospective studies and 15 case
214 reports/series were included in the systematic review. A 2008 retrospective study by
215 Reed and colleagues was one of the first to suggest a benefit to polyene-echinocandin
216 combination therapy for primary treatment of rhino-orbital-cerebral mucormycosis
217 (ROCM). Amongst 41 patients with ROCM (83% diabetic) between 1994-2006 at two
218 centers, 100% (7 of 7) of patients receiving lipid-complex AmB (ABLc) or L-AmB plus
219 CAS were alive and not in hospital care 30 days after hospital discharge vs. 45%
220 (15/34) of patients on dAmB or a lipid formulation alone ($P=0.02$). (60) In a multivariate

221 analysis, only receipt of combination therapy was significantly associated with improved
222 outcome (OR, 10.9; $P=0.02$).

223 Kyvernitakis and colleagues performed the largest analysis to date in a
224 retrospective study including 106 HM and HCT patients with mucormycosis at a single
225 U.S. cancer center between 1994-2014.(61) For initial therapy, 44% of patients
226 received monotherapy (L-AmB 87%, POS 13%) and 56% of patients received CAF (L-
227 AmB + echinocandin, 46%; L-AmB + POS, 27%; triple therapy, 27%), highlighting the
228 frequency with which CAF is employed in clinical practice. Using a propensity-score
229 adjusted analysis, they found a similar 6-week survival between patients receiving initial
230 monotherapy vs. combination therapy (56% vs. 60%; $P=0.71$).

231 An important feature of the abovementioned studies is the relatively long study
232 period spanning over 10 years, which may introduce biases pertaining to changes in
233 fungal diagnostics, supportive care practices, and availability of specific antifungal
234 agents and formulations. An additional limitation to observational studies of IFD
235 treatment is the use of different dosages of antifungal agents, which may affect efficacy
236 and toxicity.

237 **Animal studies of combination antifungal therapy**

238 In the absence of large-scale RCTs, animal models of IFDs have several
239 strengths. They allow for pharmacokinetics of the administered drugs, tissue burden,
240 and rate of clearance to be assessed. Researchers can integrate host factors and
241 study a range of doses and dose combinations. Finally, resistant species may be
242 studied; whereas, enrolling patients with rare and highly resistant fungal pathogen into

243 clinical trials is quite challenging. With the implementation of ARRIVE (Animal
244 Research: Reporting In Vivo Experiments) and ARRIVE 2.0 guidelines on the design,
245 conduct, and reporting of animal studies, it is reasonable to conclude that animal
246 studies with IFD and CAF will be able to bridge the quality gap with RCTs.(62-64)
247 *Candida spp.*

248 Studies of CAF in experimental models of infections due to *Candida spp.* have
249 yielded mixed results depending on the species, drugs, and methodology. For example,
250 the combination of FLC plus CAS for murine candidemia (*C. albicans*) yielded no
251 change in tissue fungal burden as compared to FLC monotherapy; whereas POS plus
252 CAS led to improved survival compared to either drug alone.(65, 66)

253 An *in vivo* study by Louie and colleagues further illustrates the complexity of
254 antifungal interactions.(67, 68) In a rabbit model of *Candida albicans* endocarditis and
255 pyelonephritis, both AmB monotherapy and sequential treatment with AmB alone
256 followed by AmB plus FLC rapidly sterilized kidneys and cardiac vegetations. In
257 contrast, simultaneous AmB plus FLC, FLC monotherapy, and FLC followed by AmB
258 were all slower to clear fungi from infected tissues.(68)

259 Polyene-echinocandin combination is the most frequently studied regimen in the
260 experimental models of IC, particularly due to *C. glabrata*. Compared to monotherapy,
261 AmB plus CAS or L-AmB plus CAS or micafungin (MFG) led to reduced tissue fungal
262 burden in a murine model of systemic infection due to azole-resistant *C. albicans* and *C.*
263 *glabrata* and in immunosuppressed mice with *C. glabrata* infection.(69-71)

264 *Cryptococcus spp.*

265 *In vivo* studies of CAF for cryptococcosis laid the groundwork for subsequent
266 RCTs in humans. In particular, AmB, FLC, and 5-FC, in different dosages and
267 combinations, have been extensively studied in animal models of disseminated disease
268 and meningitis. Schwarz and colleagues demonstrated that AmB plus 5-FC, as
269 compared to monotherapy, led to improved survival and reduced brain tissue fungal
270 burden in murine disseminated cryptococcosis due to 5-FC-susceptible or -resistant *C.*
271 *neoformans*.(72) Other studies have found that FLC and AmB, whether given
272 sequentially or combined, lead to greater antifungal activity than AmB alone.(73, 74)
273 The role of high-dose FLC, with or without 5-FC, was further established in murine
274 cryptococcal meningitis.(75)

275 Other triazoles have received lesser attention, either as monotherapy or
276 combination therapy, in experimental models of cryptococcosis.(76)

277 *Aspergillus spp.*

278 Preclinical studies of azole-echinocandin combinations for IA have garnered
279 significant interest given the favorable safety profile of the latter group. The
280 combinations of POS plus AFG and ISA plus MFG led to improved outcomes in
281 neutropenic models of IA.(77, 78) This synergistic interaction between the
282 echinocandin and the triazole is likely due to simultaneous inhibition of biosynthesis of
283 1,3- β -D-glucan in the fungal cell wall and ergosterol in the cell membrane. However,
284 poorer outcomes observed with VOR plus high-dose AFG suggest that azole-
285 echinocandin interactions may be concentration-dependent.(79)

286 Experimental models of IA treated with azole-polyene combinations have
287 primarily demonstrated antagonism except for CNS disease.(79-82) Again,
288 consideration of the drug mechanism of action may explain these observations.
289 Antifungal azoles deplete the fungal cell membrane of ergosterol and thereby diminish
290 the principal biochemical target of AmB.

291 Polyene-echinocandins combination did not show any benefit for experimental
292 CNS aspergillosis or for invasive pulmonary aspergillosis in immunosuppressed murine
293 models due to chronic granulomatous disease or glucocorticoids.(82-84)

294 *Mucorales*

295 Azole-polyene combinations for treatment of mucormycosis are frequently used
296 in clinical practice, although preclinical data do not clearly establish a benefit. In
297 neutropenic mice with pulmonary mucormycosis due to *R. delemar* or *M. circinelloides*,
298 L-AmB plus ISA improved survival and reduced tissue fungal burden (lung and brain)
299 compared to either drug alone.(85) However, in murine disseminated mucormycosis
300 due to *R. oryzae*, L-AmB plus POS did not improve outcomes as compared to L-AmB
301 monotherapy.(86, 87)

302 Echinocandins do not have *in vitro* activity against Mucorales in standard
303 susceptibility tests, however, some agents of mucormycosis, including *Rhizopus oryzae*,
304 express (1→3)-β-D-glucan synthase, which is the target enzyme for echinocandins.(88)
305 Experimental studies of murine mucormycosis due to *R. oryzae* have found improved
306 outcomes when combining lipid formulations of Amb plus echinocandins as compared
307 to either agent alone.(89, 90) The benefit noted with the addition of echinocandins may

308 be in part due to the class' immunomodulatory effect on the activity of phagocytic
309 cells.(91) However, no evidence of synergy nor antagonism was noted for the
310 combination of ISA and MFG in neutropenic mice with pulmonary disease due to *R.*
311 *delemar*.(92)

312 **Laboratory methods**

313 There are no standard CLSI or EUCAST methods for *in vitro* testing of antifungal
314 agents in combinations (93). Our literature analysis revealed numerous publications on
315 laboratory testing of antifungal drugs in combinations against yeasts and molds
316 (Supplementary Fig 1). Only a small selection of published studies included details
317 consistent with the inoculum, inclusion of quality control strains, end-point reading, and
318 interpretations of test results per CLSI or EUCAST methods for testing of molds and
319 yeasts (94-112). Even publications describing combination testing with standard
320 methods originated from single institutions and the reproducibility of the described
321 method at other institutions remains unknown. The development of a consensus
322 method with standardized parameters is imperative for the meaningful testing of
323 antifungal combinations in the clinical laboratory. Towards this end, one of us
324 conducted a series of multi-laboratory studies to define the parameters that would allow
325 reproducible antifungal combination testing. We identified a *Candida krusei* QC strain,
326 inoculum size, and 100% inhibition end-point as highly reproducible features for
327 combination testing of *Candida* species and *Aspergillus fumigatus* among six
328 laboratories (113-115). The result interpretations were consistent among laboratories
329 using summation fractional inhibitory concentration indices (Σ FICI) (113, 116). Recent
330 re-analysis of the data revealed significant pharmacodynamic interactions with Loewe

331 additivity-based FIC_i range of 1–2 FIC and essential agreement with Bliss
332 independence-based response surface analysis (116). Thus, laboratories now have
333 access to a standardized method for *in vitro* testing of antifungal agents in
334 combinations. Further progress is imminent when multi-laboratory studies are
335 conducted with newer antifungal combinations and with other fungal pathogens.
336 Similarly, there is an opportunity for device manufacturers to offer commercial
337 combination panels for wider access to routine laboratory testing.

338 **Future prospects**

339 Table 2 summarizes ongoing clinical trials of CAF, including those incorporating
340 investigational and non-systemic (e.g., aerosolized) antifungal agents. Promising drugs
341 in clinical phases of development with novel mechanisms of action include
342 fosmanogepix, olorofim, and ibrexafungerp.(117) These agents offer hope to expand
343 our antifungal armamentarium, particularly against resistant yeasts and molds, yet will
344 face the same environmental and host pressures for emergence of resistance over time.
345 As such, drug development research should investigate these compounds in
346 combinations and even look towards an antifungal “polypill” that might improve patient
347 adherence and lessen healthcare costs.(23, 118)

348 While our review focused on a combinatorial strategy involving antifungal drugs,
349 a particularly novel and emerging area of research is the role of cancer
350 immunotherapies as adjunctive therapy for IFDs. Evidence that fungi induce activation
351 of checkpoint pathways has led to preclinical data demonstrating that blockade of the
352 Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-Lymphocyte Antigen 4
353 pathways augments antifungal immunity and improves outcomes.(119) Thus far,

354 clinical data are limited to case reports for invasive mold diseases.(120, 121) Besides
355 providing support towards future interventional trials, such investigations of
356 immunomodulatory therapies to combat IFDs highlight the need to understand the role
357 of host immune responses in the outcomes of IFDs when designing and interpreting
358 experimental and clinical studies of CAF.

359 **Conclusion**

360 Our systematic review of the literature highlights the paucity of rigorous clinical
361 investigations of CAF for invasive candidiasis and mucormycosis; whereas, multiple
362 RCTs establish the superiority of polyene-5-FC CAF for cryptococcosis and one large
363 RCT of azole-echinocandin CAF for IA suggests a benefit in patients with hematologic
364 malignancy and probable IA. Given the challenges to conducting large prospective
365 RCTs for most IFDs, it is reasonable to prioritize future trials of CAF based upon animal
366 models demonstrating improved survival and observational clinical data supporting
367 efficacy and safety. Recent multi-laboratory investigations demonstrated the feasibility
368 of a standardized method of *in vitro* testing of antifungal combinations for *Candida*
369 species that should be further investigated with other pathogen and drug combinations.

370

371

372

373

374

375 Author contributions. S.J. and V.C: Conceptualization, systematic literature review,
376 writing of original draft, and review and editing.

377 Conflict of interest: The authors have no conflicts of interest to declare.

378 Funding: None.

379 Patient consent statement: Not applicable.

380

381 References

382

- 383 1. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: Human
384 fungal infections. *Science Translational Medicine*. 2012;4(165):1-10.
- 385 2. Seagle EE, Williams SL, Chiller TM. Recent Trends in the Epidemiology of Fungal Infections.
386 *Infectious Disease Clinics of North America*. 2021;35(2):237-60.
- 387 3. Chowdhary A, Gupta N, Wurster S, Kumar R, Mohabir JT, Tatarvarthy S, et al. Multimodal analysis
388 of the COVID-19-associated mucormycosis outbreak in Delhi, India indicates the convergence of clinical
389 and environmental risk factors. *Mycoses*. 2023;66(6):515-26.
- 390 4. Steinbrink JM, Hong DK, Bergin SP, Al-Rohil RN, Perfect JR, Maziarz EK. The robust and rapid role
391 of molecular testing in precision fungal diagnostics: A case report. *Med Mycol Case Rep*. 2020;27:77-80.
- 392 5. Consortium O, Gabaldon T. Recent trends in molecular diagnostics of yeast infections: from PCR
393 to NGS. *FEMS Microbiol Rev*. 2019;43(5):517-47.
- 394 6. White PL, Alanio A, Brown L, Cruciani M, Hagen F, Gorton R, et al. An overview of using fungal
395 DNA for the diagnosis of invasive mycoses. *Expert Rev Mol Diagn*. 2022;22(2):169-84.
- 396 7. Benedict K, Whitham HK, Jackson BR. Economic Burden of Fungal Diseases in the United States.
397 *Open Forum Infectious Diseases*. 2022;9(4):6-9.
- 398 8. Rayens E, Norris KA. Prevalence and Healthcare Burden of Fungal Infections in the United States,
399 2018. *Open Forum Infectious Diseases*. 2022;9(1).
- 400 9. Valerio M, Rodriguez-Gonzalez CG, Munoz P, Caliz B, Sanjurjo M, Bouza E, et al. Evaluation of
401 antifungal use in a tertiary care institution: antifungal stewardship urgently needed. *J Antimicrob*
402 *Chemother*. 2014;69(7):1993-9.
- 403 10. Kara E, Metan G, Bayraktar-Ekincioglu A, Gulmez D, Arikan-Akdagli S, Demirkazik F, et al.
404 Implementation of Pharmacist-Driven Antifungal Stewardship Program in a Tertiary Care Hospital.
405 *Antimicrob Agents Chemother*. 2021;65(9):e0062921.
- 406 11. Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of
407 invasive candidiasis. *Journal of Antimicrobial Chemotherapy*. 2018;73:i4-i13.
- 408 12. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID guideline
409 for the diagnosis and management of *Candida* diseases 2012: Non-neutropenic adult patients. *Clinical*
410 *Microbiology and Infection*. 2012;18(SUPPL. 7):19-37.
- 411 13. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical
412 Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society
413 of America. *Clinical Infectious Diseases*. 2015;62(4):e1-e50.
- 414 14. Patterson TF, Thompson GR, 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice
415 Guidelines for the Diagnosis and Management of Aspergillosis : 2016 Update by the Infectious Diseases
416 Society of America. *Clinical Infectious Diseases*. 2016;63:1-60.
- 417 15. Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and
418 management of *Aspergillus* diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.
419 *Clinical Microbiology and Infection*. 2018;24:e1-e38.
- 420 16. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global
421 guideline for the diagnosis and management of mucormycosis: an initiative of the European
422 Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and
423 Research Consortium. *The Lancet Infectious Diseases*. 2019;19(12):e405-e21.
- 424 17. Organization WH. Guidelines for diagnosing, preventing and managing cryptococcal disease
425 among adults, adolescents and children living with HIV Geneva2022 [updated 27 June 2022. Available
426 from: <https://www.who.int/publications/i/item/9789240052178>.

- 427 18. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and
428 Adolescents with HIV 2021 [Available from: [https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-](https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/cryptococcosis?view=full)
429 [guidelines-adult-and-adolescent-opportunistic-infections/cryptococcosis?view=full](https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/cryptococcosis?view=full).
430 19. Chang CC, Harrison TS, Bicanic TA, Chayakulkeeree M, Sorrell TC, Warris A, et al. Global guideline
431 for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in
432 cooperation with the ASM. *Lancet Infect Dis*. 2024.
433 20. Johnson MD, Perfect JR. Use of Antifungal Combination Therapy: Agents, Order, and Timing.
434 *Current Fungal Infection Reports*. 2010;4(2):87-95.
435 21. Tyers M, Wright GD. Drug combinations: a strategy to extend the life of antibiotics in the 21st
436 century. *Nat Rev Microbiol*. 2019;17(3):141-55.
437 22. Coates ARM, Hu Y, Holt J, Yeh P. Antibiotic combination therapy against resistant bacterial
438 infections: synergy, rejuvenation and resistance reduction. *Expert Rev Anti Infect Ther*. 2020;18(1):5-15.
439 23. Wake RM, Allebone-Salt PE, John LLH, Caswall BA, Govender NP, Ben-Ami R, et al. Optimising
440 the Treatment of Invasive Candidiasis – A Case for Combination Therapy. *Open Forum Infectious*
441 *Diseases*. 2024.
442 24. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. *N Engl J*
443 *Med*. 1997;336(21):1531-2.
444 25. Collaboration H-C, Ray M, Logan R, Sterne JA, Hernandez-Diaz S, Robins JM, et al. The effect of
445 combined antiretroviral therapy on the overall mortality of HIV-infected individuals. *AIDS*.
446 2010;24(1):123-37.
447 26. Kerantzas CA, Jacobs WR, Jr. Origins of Combination Therapy for Tuberculosis: Lessons for
448 Future Antimicrobial Development and Application. *mBio*. 2017;8(2).
449 27. Marshall HT, Djamgoz MBA. Immuno-Oncology: Emerging Targets and Combination Therapies.
450 *Front Oncol*. 2018;8:315.
451 28. Spellberg B, Ibrahim A, Roilides E, Lewis RE, Lortholary O, Petrikos G, et al. Combination
452 therapy for mucormycosis: Why, what, and how? *Clinical Infectious Diseases*. 2012;54(SUPPL. 1):73-8.
453 29. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020
454 statement: An updated guideline for reporting systematic reviews. *J Clin Epidemiol*. 2021;134:178-89.
455 30. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and
456 Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for
457 Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.
458 *Clin Infect Dis*. 2020;71(6):1367-76.
459 31. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions
460 of invasive fungal disease from the European Organization for Research and Treatment of
461 Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious
462 Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clin Infect Dis*. 2008;46(12):1813-21.
463 32. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, et al. A randomized and blinded
464 multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as
465 therapy for candidemia and its consequences in nonneutropenic subjects. *Clin Infect Dis*.
466 2003;36(10):1221-8.
467 33. Abele-Horn M, Kopp A, Sternberg U, Ohly A, Dauber A, Russwurm W, et al. A randomized study
468 comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic *Candida*
469 infections in intensive care patients. *Infection*. 1996;24(6):426-32.
470 34. Pelletier R, Alarie I, Lagace R, Walsh TJ. Emergence of disseminated candidiasis caused by
471 *Candida krusei* during treatment with caspofungin: case report and review of literature. *Med Mycol*.
472 2005;43(6):559-64.

- 473 35. Wong PN, Lo KY, Tong GM, Chan SF, Lo MW, Mak SK, et al. Treatment of fungal peritonitis with a
474 combination of intravenous amphotericin B and oral flucytosine, and delayed catheter replacement in
475 continuous ambulatory peritoneal dialysis. *Perit Dial Int*. 2008;28(2):155-62.
- 476 36. Ahuja T, Fong K, Louie E. Combination antifungal therapy for treatment of *Candida parapsilosis*
477 prosthetic valve endocarditis and utility of T2Candida Panel(R): A case series. *IDCases*. 2019;15:e00525.
- 478 37. Wee LE, Wong CSL, Tan AL, Oh HM. Negative cerebrospinal fluid beta-d-glucan levels as an
479 indicator for treatment cessation ahead of biochemical resolution: A case report of *Candida glabrata*
480 meningitis. *Med Mycol Case Rep*. 2021;32:47-9.
- 481 38. O'Brien B, Chaturvedi S, Chaturvedi V. In Vitro Evaluation of Antifungal Drug Combinations
482 against Multidrug-Resistant *Candida auris* Isolates from New York Outbreak. *Antimicrobial Agents and*
483 *Chemotherapy*. 2020;64(4).
- 484 39. Kethireddy S, Andes D. CNS pharmacokinetics of antifungal agents. *Expert Opin Drug Metab*
485 *Toxicol*. 2007;3(4):573-81.
- 486 40. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, et al. Combination
487 antifungal therapies for HIV-associated cryptococcal meningitis: A randomised trial. *Lancet*.
488 2004;363(9423):1764-7.
- 489 41. Day JN, Chau TTH, Wolbers M, Mai PP, Dung NT, Mai NH, et al. Combination Antifungal Therapy
490 for Cryptococcal Meningitis. *New England Journal of Medicine*. 2013;368(14):1291-302.
- 491 42. Pappas PG, Chetchotisakd P, Larsen RA, Manosuthi W, Morris MI, Anekthananon T, et al. A
492 phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-
493 associated cryptococcal meningitis. *Clin Infect Dis*. 2009;48(12):1775-83.
- 494 43. Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA, et al. Toxicity of
495 amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. *Am J Med*. 1987;83(2):236-
496 42.
- 497 44. Molloy SF, Kanyama C, Heyderman RS, Loyse A, Kouanfack C, Chanda D, et al. Antifungal
498 Combinations for Treatment of Cryptococcal Meningitis in Africa. *N Engl J Med*. 2018;378(11):1004-17.
- 499 45. Jarvis JN, Lawrence DS, Meya DB, Kagimu E, Kasibante J, Mpoza E, et al. Single-Dose Liposomal
500 Amphotericin B Treatment for Cryptococcal Meningitis. *N Engl J Med*. 2022;386(12):1109-20.
- 501 46. Hurt WJ, Harrison TS, Molloy SF, Bicanic TA. Combination Therapy for HIV-Associated
502 Cryptococcal Meningitis-A Success Story. *J Fungi (Basel)*. 2021;7(12).
- 503 47. Diamond DM, Bauer M, Daniel BE, Leal MA, Johnson D, Williams BK, et al. Amphotericin B
504 colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine
505 cryptococcal meningitis. *Antimicrob Agents Chemother*. 1998;42(3):528-33.
- 506 48. Thompson GR, 3rd, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF.
507 Antifungal susceptibilities among different serotypes of *Cryptococcus gattii* and *Cryptococcus*
508 *neoformans*. *Antimicrob Agents Chemother*. 2009;53(1):309-11.
- 509 49. Loyse A, Wilson D, Meintjes G, Jarvis JN, Bicanic T, Bishop L, et al. Comparison of the early
510 fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in
511 combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. *Clin*
512 *Infect Dis*. 2012;54(1):121-8.
- 513 50. Caillot D, Thiébaud A, Herbrecht R, de Botton S, Pigneux A, Bernard F, et al. Liposomal
514 amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic
515 malignancies: a randomized pilot study (Combistrat trial). *Cancer*. 2007;110(12):2740-6.
- 516 51. Raad, II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, et al. Novel antifungal agents as
517 salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole
518 compared with high-dose lipid formulations of amphotericin B alone or in combination with
519 caspofungin. *Leukemia*. 2008;22(3):496-503.

- 520 52. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following
521 hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. *Clin*
522 *Infect Dis.* 2007;44(4):531-40.
- 523 53. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al.
524 Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med.*
525 2002;347(6):408-15.
- 526 54. Marr KA, Boeckh M, Carter RA, Hyung WK, Corey L. Combination antifungal therapy for invasive
527 aspergillosis. *Clinical Infectious Diseases.* 2004;39(6):797-802.
- 528 55. Raad, II, Zakhem AE, Helou GE, Jiang Y, Kontoyiannis DP, Hachem R. Clinical experience of the
529 use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive
530 aspergillosis in haematological malignancies. *Int J Antimicrob Agents.* 2015;45(3):283-8.
- 531 56. Singh N, Limaye AP, Forrest G, Safdar N, Muñoz P, Pursell K, et al. Combination of voriconazole
532 and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a
533 prospective, multicenter, observational study. *Transplantation.* 2006;81(3):320-6.
- 534 57. Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, et al. Combination
535 antifungal therapy for invasive aspergillosis: a randomized trial. *Ann Intern Med.* 2015;162(2):81-9.
- 536 58. Kontoyiannis DP, Boktour M, Hanna H, Torres HA, Hachem R, Raad, II. Itraconazole added to a
537 lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive
538 aspergillosis. *Cancer.* 2005;103(11):2334-7.
- 539 59. Rojas R, Molina JR, Jarque I, Montes C, Serrano J, Sanz J, et al. Outcome of Antifungal
540 Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the
541 Chosen Combination. *Mediterr J Hematol Infect Dis.* 2012;4(1):e2012011.
- 542 60. Reed C, Bryant R, Ibrahim AS, Edwards J, Jr., Filler SG, Goldberg R, et al. Combination polyene-
543 caspofungin treatment of rhino-orbital-cerebral mucormycosis. *Clin Infect Dis.* 2008;47(3):364-71.
- 544 61. Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of
545 combination treatment does not impact survival of 106 patients with haematologic malignancies and
546 mucormycosis: a propensity score analysis. *Clinical Microbiology and Infection.* 2016;22(9):811.e1-.e8.
- 547 62. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research
548 reporting: the ARRIVE guidelines for reporting animal research. *PLoS Biol.* 2010;8(6):e1000412.
- 549 63. Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, et al. Reporting animal
550 research: Explanation and elaboration for the ARRIVE guidelines 2.0. *PLoS Biol.* 2020;18(7):e3000411.
- 551 64. Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines
552 2.0: Updated guidelines for reporting animal research. *J Cereb Blood Flow Metab.* 2020;40(9):1769-77.
- 553 65. Graybill JR, Bocanegra R, Najvar LK, Hernandez S, Larsen RA. Addition of caspofungin to
554 fluconazole does not improve outcome in murine candidiasis. *Antimicrob Agents Chemother.*
555 2003;47(7):2373-5.
- 556 66. Chen YL, Lehman VN, Averette AF, Perfect JR, Heitman J. Posaconazole exhibits in vitro and in
557 vivo synergistic antifungal activity with caspofungin or FK506 against *Candida albicans*. *PLoS One.*
558 2013;8(3):e57672.
- 559 67. Fioriti S, Brescini L, Pallotta F, Canovari B, Morroni G, Barchiesi F. Antifungal Combinations
560 against *Candida* Species: From Bench to Bedside. *J Fungi (Basel).* 2022;8(10).
- 561 68. Louie A, Kaw P, Banerjee P, Liu W, Chen G, Miller MH. Impact of the order of initiation of
562 fluconazole and amphotericin B in sequential or combination therapy on killing of *Candida albicans* in
563 vitro and in a rabbit model of endocarditis and pyelonephritis. *Antimicrob Agents Chemother.*
564 2001;45(2):485-94.
- 565 69. Hossain MA, Reyes GH, Long LA, Mukherjee PK, Ghannoum MA. Efficacy of caspofungin
566 combined with amphotericin B against azole-resistant *Candida albicans*. *J Antimicrob Chemother.*
567 2003;51(6):1427-9.

- 568 70. Barchiesi F, Spreghini E, Fothergill AW, Arzeni D, Greganti G, Giannini D, et al. Caspofungin in
569 combination with amphotericin B against *Candida glabrata*. *Antimicrob Agents Chemother.*
570 2005;49(6):2546-9.
- 571 71. Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT. Treatment of *Candida glabrata* infection in
572 immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or
573 micafungin. *Antimicrob Agents Chemother.* 2005;49(12):4895-902.
- 574 72. Schwarz P, Dromer F, Lortholary O, Dannaoui E. Efficacy of amphotericin B in combination with
575 flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of *Cryptococcus neoformans*
576 during disseminated murine cryptococcosis. *Antimicrob Agents Chemother.* 2006;50(1):113-20.
- 577 73. Larsen RA, Bauer M, Thomas AM, Graybill JR. Amphotericin B and fluconazole, a potent
578 combination therapy for cryptococcal meningitis. *Antimicrob Agents Chemother.* 2004;48(3):985-91.
- 579 74. Barchiesi F, Schimizzi AM, Caselli F, Novelli A, Fallani S, Giannini D, et al. Interactions between
580 triazoles and amphotericin B against *Cryptococcus neoformans*. *Antimicrob Agents Chemother.*
581 2000;44(9):2435-41.
- 582 75. Hossain MA, Mukherjee PK, Reyes G, Long L, Ghannoum MA. Effects of fluconazole singly and in
583 combination with 5-fluorocytosine or amphotericin B in the treatment of cryptococcal
584 meningoencephalitis in an intracranial murine model. *J Chemother.* 2002;14(4):351-60.
- 585 76. Silva EG, Paula CR, Dias AL, Chang MR, Ruiz Lda S, Gambale V, et al. Combination efficacy of
586 voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by
587 fluconazole-resistant *Cryptococcus neoformans*. *Mycopathologia.* 2011;171(4):261-6.
- 588 77. Martin-Vicente A, Capilla J, Guarro J. Synergistic effect of anidulafungin combined with
589 posaconazole in experimental aspergillosis. *Med Mycol.* 2017;55(4):457-60.
- 590 78. Petraitis V, Petraitiene R, McCarthy MW, Kovanda LL, Zaw MH, Hussain K, et al. Combination
591 Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary
592 Aspergillosis. *Antimicrob Agents Chemother.* 2017;61(9).
- 593 79. Petraitis V, Petraitiene R, Hope WW, Meletiadiis J, Mickiene D, Hughes JE, et al. Combination
594 Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the
595 Concentration- and Dose- Dependent Interactions between Anidulafungin and Voriconazole by Bliss
596 Independence Drug Interaction Analysis. *Antimicrobial agents and chemotherapy.* 2009;53(6):2382-91.
- 597 80. Schaffner A, Frick PG. The effect of ketoconazole on amphotericin B in a model of disseminated
598 aspergillosis. *J Infect Dis.* 1985;151(5):902-10.
- 599 81. Martin-Vicente A, Capilla J, Guarro J. In Vivo Synergy of Amphotericin B plus Posaconazole in
600 Murine Aspergillosis. *Antimicrob Agents Chemother.* 2016;60(1):296-300.
- 601 82. Clemons KV, Parmar R, Martinez M, Stevens DA. Efficacy of Abelcet alone, or in combination
602 therapy, against experimental central nervous system aspergillosis. *J Antimicrob Chemother.*
603 2006;58(2):466-9.
- 604 83. Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against experimental
605 pulmonary aspergillosis. *Med Mycol.* 2006;44(1):69-73.
- 606 84. Dennis CG, Greco WR, Brun Y, Youn R, Slocum HK, Bernacki RJ, et al. Effect of amphotericin B
607 and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis
608 in the p47phox^{-/-} mouse model of chronic granulomatous disease. *Antimicrob Agents Chemother.*
609 2006;50(2):422-7.
- 610 85. Gebremariam T, Gu Y, Singh S, Kitt TM, Ibrahim AS. Combination treatment of liposomal
611 amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis. *J Antimicrob*
612 *Chemother.* 2021;76(10):2636-9.
- 613 86. Ibrahim AS, Gebremariam T, Schwartz JA, Edwards JE, Jr., Spellberg B. Posaconazole mono- or
614 combination therapy for treatment of murine zygomycosis. *Antimicrob Agents Chemother.*
615 2009;53(2):772-5.

- 616 87. Rodríguez MM, Serena C, Mariné M, Pastor FJ, Guarro J. Posaconazole combined with
617 amphotericin B, an effective therapy for a murine disseminated infection caused by *Rhizopus oryzae*.
618 *Antimicrob Agents Chemother*. 2008;52(10):3786-8.
- 619 88. Ibrahim AS, Bowman JC, Avanesian V, Brown K, Spellberg B, Edwards JE, Jr., et al. Caspofungin
620 inhibits *Rhizopus oryzae* 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative
621 PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.
622 *Antimicrob Agents Chemother*. 2005;49(2):721-7.
- 623 89. Spellberg B, Fu Y, Edwards JE, Jr., Ibrahim AS. Combination therapy with amphotericin B lipid
624 complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. *Antimicrob*
625 *Agents Chemother*. 2005;49(2):830-2.
- 626 90. Ibrahim AS, Gebremariam T, Fu Y, Edwards JE, Jr., Spellberg B. Combination echinocandin-
627 polyene treatment of murine mucormycosis. *Antimicrob Agents Chemother*. 2008;52(4):1556-8.
- 628 91. Lamaris GA, Lewis RE, Chamilos G, May GS, Safdar A, Walsh TJ, et al. Caspofungin-mediated
629 beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against
630 *Aspergillus* and non-*Aspergillus* hyphae. *J Infect Dis*. 2008;198(2):186-92.
- 631 92. Gebremariam T, Wiederhold NP, Alqarihi A, Uppuluri P, Azie N, Edwards JE, Jr., et al.
632 Monotherapy or combination therapy of isavuconazole and micafungin for treating murine
633 mucormycosis. *J Antimicrob Chemother*. 2017;72(2):462-6.
- 634 93. Bidaud A-L, Schwarz P, Herbreteau G, Dannaoui E. Techniques for the assessment of in vitro and
635 in vivo antifungal combinations. *Journal of Fungi*. 2021;7(2):113.
- 636 94. Meletiadiis J, Beredaki MI, Elefanti A, Pournaras S, Muller A. In Vitro-In Vivo Correlation of
637 Posaconazole-Amphotericin B Combination against *Candida albicans*: In Vitro Interacting Concentrations
638 Are Associated with In Vivo Free Drug Levels. *J Fungi (Basel)*. 2023;9(4).
- 639 95. John LL, Thomson DD, Bicanic T, Hoenigl M, Brown AJ, Harrison TS, et al. Heightened efficacy of
640 anidulafungin when used in combination with manogepix or 5-flucytosine against *Candida auris* in vitro.
641 *Antimicrob Agents Ch*. 2023:e01645-22.
- 642 96. O'Brien B, Chaturvedi S, Chaturvedi V. In vitro evaluation of antifungal drug combinations
643 against multidrug-resistant *Candida auris* isolates from New York outbreak. *Antimicrobial agents and*
644 *chemotherapy*. 2020;64(4):10.1128/aac.02195-19.
- 645 97. Shi C, Liu CL, Liu JY, Wang Y, Li J, Xiang MJ. Anti-*Candida* Activity of New Azole Derivatives Alone
646 and in Combination with Fluconazole. *Mycopathologia*. 2015;180(3-4):203-7.
- 647 98. Planche V, Ducroz S, Alanio A, Bougnoux ME, Lortholary O, Dannaoui E. In vitro combination of
648 anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant *Aspergillus* spp.
649 *Antimicrob Agents Chemother*. 2012;56(8):4500-3.
- 650 99. Venturini TP, Rossato L, Spader TB, Tronco-Alves GR, Azevedo MI, Weiler CB, et al. In vitro
651 synergisms obtained by amphotericin B and voriconazole associated with non-antifungal agents against
652 *Fusarium* spp. *Diagn Microbiol Infect Dis*. 2011;71(2):126-30.
- 653 100. Ben-Ami R, Lewis RE, Kontoyiannis DP. In vitro interactions among echinocandins against
654 *Aspergillus fumigatus*: lack of concordance among methods. *Medical mycology*. 2011;49(3):285-8.
- 655 101. Cuenca-Estrella M, Alastruey-Izquierdo A, Alcazar-Fuoli L, Bernal-Martinez L, Gomez-Lopez A,
656 Buitrago MJ, et al. In vitro activities of 35 double combinations of antifungal agents against
657 *Scedosporium apiospermum* and *Scedosporium prolificans*. *Antimicrob Agents Ch*. 2008;52(3):1136-9.
- 658 102. Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. Comparative in vitro activities of
659 posaconazole, voriconazole, itraconazole, and amphotericin B against *Aspergillus* and *Rhizopus*, and
660 synergy testing for *Rhizopus*. *Sabouraudia*. 2008;46(6):567-73.
- 661 103. Cuenca-Estrella M, Gomez-Lopez A, Buitrago MJ, Mellado E, Garcia-Effron G, Rodriguez-Tudela
662 JL. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen
663 *Scopulariopsis brevicaulis*. *Antimicrob Agents Ch*. 2006;50(6):2248-50.

- 664 104. Philip A, Odabasi Z, Rodriguez J, Paetznick VL, Chen E, Rex JH, et al. In vitro synergy testing of
665 anidulafungin with itraconazole, voriconazole, and amphotericin B against *Aspergillus* spp. and *Fusarium*
666 spp. *Antimicrob Agents Ch.* 2005;49(8):3572-4.
- 667 105. Lewis RE, Kontoyiannis DP. Micafungin in combination with voriconazole in *Aspergillus* species: a
668 pharmacodynamic approach for detection of combined antifungal activity in vitro. *J Antimicrob*
669 *Chemoth.* 2005;56(5):887-92.
- 670 106. Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G, Alcazar-Fuoli L, Mellado E, Buitrago MJ, et
671 al. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-
672 resistant clinical isolates of *Aspergillus fumigatus*. *Antimicrob Agents Ch.* 2005;49(3):1232-5.
- 673 107. Srimuang S, Prariyachatigul C, Chaiprasert A, Rungsipanuratn W, Tanphaichitra D. Antifungal
674 drug combinations for *Cryptococcus neoformans* and *Prototheca* spp. *J Med Assoc Thai.* 2000;83(1):57-
675 60.
- 676 108. Barchiesi F, Di Francesco LF, Compagnucci P, Arzeni D, Giacometti A, Scalise G. In-vitro
677 interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of
678 *Candida albicans*. *J Antimicrob Chemother.* 1998;41(1):59-65.
- 679 109. Hanson LH, Stevens DA. Comparison of antifungal activity of amphotericin B deoxycholate
680 suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. *Antimicrob Agents*
681 *Chemother.* 1992;36(2):486-8.
- 682 110. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational
683 Supplement. CLSI document M100-S25. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.
684 2015.
- 685 111. CLSI. Performance standards for antifungal susceptibility testing of yeasts: CLSI supplement
686 M60. Wayne, PA, USA: CLSI; 2017.
- 687 112. Meletiadiis J, Pournaras S, Roilides E, Walsh TJ. Defining fractional inhibitory concentration index
688 cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation
689 analysis, and in vitro-in vivo correlation data for antifungal drug combinations against *Aspergillus*
690 *fumigatus*. *Antimicrob Agents Chemother.* 2010;54(2):602-9.
- 691 113. Ren P, Luo M, Lin S, Ghannoum MA, Isham N, Diekema DJ, et al. Multilaboratory testing of
692 antifungal drug combinations against *Candida* species and *Aspergillus fumigatus*: utility of 100 percent
693 inhibition as the endpoint. *Antimicrobial Agents and Chemotherapy.* 2015;59(3):1759-66.
- 694 114. Chaturvedi V, Ramani R, Andes D, Diekema DJ, Pfaller MA, Ghannoum MA, et al. Multilaboratory
695 testing of two-drug combinations of antifungals against *Candida albicans*, *Candida glabrata*, and *Candida*
696 *parapsilosis*. *Antimicrob Agents Chemother.* 2011;55(4):1543-8.
- 697 115. Chaturvedi V, Ramani R, Ghannoum MA, Killian SB, Holliday N, Knapp C, et al. Multilaboratory
698 testing of antifungal combinations against a quality control isolate of *Candida krusei*. *Antimicrob Agents*
699 *Chemother.* 2008;52(4):1500-2.
- 700 116. Meletiadiis J, Andes DR, Lockhart SR, Ghannoum MA, Knapp CC, Ostrosky-Zeichner L, et al.
701 Multicenter Collaborative Study of the Interaction of Antifungal Combinations against *Candida* Spp. by
702 Loewe Additivity and Bliss Independence-Based Response Surface Analysis. *J Fungi (Basel).* 2022;8(9).
- 703 117. Jacobs SE, Zagaliotis P, Walsh TJ. Novel antifungal agents in clinical trials. *F1000Res.*
704 2021;10:507.
- 705 118. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill
706 Strategy in Secondary Cardiovascular Prevention. *N Engl J Med.* 2022;387(11):967-77.
- 707 119. Wurster S, Watowich SS, Kontoyiannis DP. Checkpoint inhibitors as immunotherapy for fungal
708 infections: Promises, challenges, and unanswered questions. *Front Immunol.* 2022;13:1018202.
- 709 120. Serris A, Ouedrani A, Uhel F, Gazzano M, Bedarida V, Rouzaud C, et al. Case Report: Immune
710 Checkpoint Blockade Plus Interferon-Gamma Add-On Antifungal Therapy in the Treatment of Refractory
711 Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis. *Front Immunol.* 2022;13:900522.

712 121. Grimaldi D, Pradier O, Hotchkiss RS, Vincent JL. Nivolumab plus interferon-gamma in the
713 treatment of intractable mucormycosis. *Lancet Infect Dis.* 2017;17(1):18.

714

715

716 **Table 1. Bird’s eye view: Summary of clinical and experimental evidence supporting**
 717 **combination antifungal therapy for the most prevalent and dangerous fungal pathogens**

Disease	Qualitative Evidence Summary
Invasive Candidiasis	<p data-bbox="440 338 1349 405">Single RCT of FLC vs. FLC + dAmB published in 2003 trended toward improved success in combination arm</p> <p data-bbox="440 438 1349 506">Experimental models of systemic <i>C. albicans</i> and <i>C. glabrata</i> infection primarily support polyene-echinocandin combination</p> <p data-bbox="440 539 1390 606">Paucity of experimental and clinical data investigating CAF for azole- and echinocandin-resistant <i>Candida</i> spp. and <i>C. auris</i></p> <p data-bbox="440 640 1333 707">No prospective trials incorporating echinocandins for CAF have been conducted</p>
Cryptococcosis	<p data-bbox="440 745 1325 842">Multiple large RCTs in HIV/AIDS-associated cryptococcal meningitis demonstrate that induction CAF with AmB + 5-FC leads to improved microbiologic and clinical outcomes compared to monotherapy</p> <p data-bbox="440 875 1349 942">Single-dose L-AmB 10 mg/kg + 14 days x 5-FC and FLC now first-line regimen in resource-limited settings</p> <p data-bbox="440 976 1386 1043">No prospective trials in non-HIV/AIDS immunocompromised hosts, nor in non-CNS manifestations of cryptococcosis</p>
Invasive Aspergillosis	<p data-bbox="440 1081 1414 1148">Single large multination RCT of VOR + AFG vs. VOR alone trended toward improved 6-week mortality in HM patients with IA (P=0.087)</p> <p data-bbox="440 1182 1341 1249">Azole-echinocandin combinations strongly supported by experimental models of IA</p> <p data-bbox="440 1283 1414 1379">Experimental studies of azole-polyene combinations primarily demonstrate antagonism; very limited clinical data show no difference compared to AmB alone</p> <p data-bbox="440 1413 1401 1480">Prospective clinical data to inform CAF for azole-resistant <i>Aspergillus</i> spp. are lacking</p>
Mucormycosis	<p data-bbox="440 1518 1341 1585">Mixed results of azole-polyene CAF from experimental data; polyene-echinocandin CAF <i>in vivo</i> synergy may be species-specific</p> <p data-bbox="440 1619 1406 1715">No prospective trials of CAF exist; largest retrospective analysis of CAF including AmB, POS, ISA and echinocandins found similar 6-week survival compared to monotherapy</p>

718 5-FC, flucytosine; AFG, anidulafungin; CAF, combination antifungal therapy; CNS, central
 719 nervous system; dAmB, deoxycholate amphotericin B; FLC, fluconazole; ISA, isavuconazole; L-
 720 AmB, liposomal amphotericin B; POS, posaconazole; RCT, randomized clinical trial; VOR,
 721 voriconazole

722 **Table 2: Ongoing clinical trials of combination antifungal therapy for invasive fungal diseases**

ClinicalTrials.gov ID	Phase	Sponsor	Disease	Treatment arms	Primary endpoint	Status
NCT03672292 Scynergia Trial	2	Scynexis, Inc., USA	Invasive pulmonary aspergillosis	Arm 1: Ibrexafungerp + voriconazole Arm 2: voriconazole+ placebo	Adverse events, death through study completion	Completed, no results posted
NCT05238116 OPERA-T Trial	3	Pulmocide Ltd, UK	Refractory invasive pulmonary aspergillosis	Arm 1: Opelconazole (inh) + systemic antifungal therapy Arm 2: Placebo (inh) + systemic antifungal therapy	Complete or partial overall response up to 12 weeks	Recruiting
NCT05541107 EnACT3 Trial	3	Matinas BioPharma Nanotechnologies, Inc., USA	Cryptococcal meningitis	Arm 1: cAMB + flucytosine induction followed by cAMB + fluconazole consolidation Arm 2: cAMB + 5 flucytosine induction followed by SOC consolidation Arm 3: SOC induction followed by SOC consolidation	All-cause mortality at 2 weeks	Not yet recruiting
NCT04502381	2	Postgraduate Institute of Medical Education and Research, India		Arm 1: Inh deoxycholate AmB + IV liposomal AmB Arm 2: IV liposomal AmB	Overall response (clinical and radiological) at 6 weeks	Completed, no results posted

723 cAmB, encochleated amphotericin B; Inh, inhaled; SOC, standard of care

724